650020 Dec 2023 12:25
4 months on
Not a single word on production
They had access to £3million in October but still we hear nothing
RNS from August is below
But if they can’t get their act together by end of H1 2024 they are finished.
The must produce and sell, produce and sell. I assume cash is the problem and I don’t know why!
Still don’t understand with 6500 ordered why you don’t get your loan. Pay the 10% for the six months you need it… or 12 or 18 months…but you have wasted almost half a year allowing something that had the appearance of being unique, being left dusty on shelves
Come on VOX. Get an interview in and ask some questions
Remember Bob likes to hit his numbers. I assume he was talking darts
Pre-commercial launch orders by leading online retailers and medical equipment providers demonstrate the scale of the demand for this transformational product
LONDON, U.K. AND PLANO, TX, U.S. (16 August 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has received purchase orders for over 6,500 of its next-generation DISCOV-R portable oxygen concentrator. This represents approximately $15 million of potential revenue to the Company, with initial production of the DISCOV-R expected to begin by the end of this quarter.
Following the pre-market launch of DISCOV-R and a patient usability study in June 2023, the Company plans a controlled roll out of the DISCOV-R this autumn and into 2024 to meet growing demand for the device amid substantial interest from medical device distributors, retailers, patients and durable medical equipment (DME) providers, among others.
The DISCOV-R is expected to be the world's first ambulatory two litre continuous flow, eight level pulse dose portable oxygen concentrator when it is released. With the ability to produce two litres of continuous flow and maximum single pulse dose volumes exceeding 110ml, the Company believes that the DISCOV-R will be covered by both CMS E1390 (stationary) and E1392 (portable) reimbursement codes, making the DISCOV-R a better financial option for the thousands of homecare oxygen providers. It will also produce nearly three times as much oxygen by weight than its dual flow competitors.
The recent purchase orders follow the signing of several distribution agreements with medical device distributors and other home healthcare providers, including a distribution agreement with a division of McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, earlier this month and a marketing agreement with GoodRx®, a leading digital healthcare platform, in February 2023. The Company has received multiple additional requests from leading oxygen homecare providers in the US to distribute the DISCOV-R.
The Company will update the market later this year as it plans its controlled roll out of the DISCOV
Sign In
Follow the stocks
